reports
- Please Change Name Jonathan Kanarek
- CFA
Moody's assigns B3 CFR to UIC Merger Sub, Inc. (dba Albany Molecular R...
Rating Action: Moody's assigns B3 CFR to UIC Merger Sub, Inc.. Global Credit Research- 19 Jul 2017. New York, July 19, 2017-- Moody's Investors Service, today assigned a B3 Corporate Family Rating and B3-PD Probability of Default Rating to UIC Merger Sub, Inc., which upon deal close will become Albany Molecular Research, Inc..
INVESTOR ALERT: Brower Piven Commences an Investigation into the Propo...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Albany Molecular Research, Inc. (Nasdaq: AMRI) (“AMRI” or the “Company”) relating to the proposed buyout of AMRI by The Carlyle Group. Under the terms of the agreement, AMRI shareholders are anticipated to receive $21.75 in cash for each share of AMRI common stock held. The ...
The Law Offices of Vincent Wong Reminds Investors of an Investigation ...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of Albany Molecular Research, Inc. (NASDAQGS:AMRI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to GTCR LLC and The Carlyle Group. Under the terms of the deal, Albany Molecular shareholders will receive $21.75 per share. The investigation concerns whether the Albany Molecular Board of Directors breached their fiduciary duties to Albany Molecular sto...
- MarketLine Department
The Law Offices of Vincent Wong Notifies Investors of an Investigation...
NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong are investigating the Board of Directors of Albany Molecular Research, Inc. (NASDAQGS: AMRI) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to GTCR LLC and The Carlyle Group. Under the terms of the deal, Albany Molecular shareholders will receive $21.75 per share. The investigation concerns whether the Albany Molecular Board of Directors breached their fiduciary duties to Albany Molecular st...
- Please Change Name Jonathan Kanarek
- CFA
Albany Molecular Research, Inc.: Update to Discussion of Key Rating Fa...
CORPORATES CREDIT OPINION 8 June 2017 Update RATINGS Albany Molecular Research, Inc. Domicile Albany, New York, United States Long Term Rating B3 , Possible Downgrade Type LT Corporate Family Ratings Outlook Rating(s) Under Review Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Jon
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Pr...
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Albany Molecular Research, Inc. (Nasdaq: AMRI) (“AMRI” or the “Company”) relating to the proposed buyout of AMRI by The Carlyle Group. Under the terms of the agreement, AMRI shareholders are anticipated to receive $21.75 in cash for each share of AMRI common stock held. The ...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investig...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Albany Molecular Research, Inc. (NASDAQGS: AMRI) stock prior to June 6, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Albany Molecular to The Carlyle Group and GTCR LLC for $21.75 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/AMRI-Info-Request-Form-ma-...
Albany Molecular Research, Inc. Shareholder Alert: Former SEC Attorney...
DALLAS--(BUSINESS WIRE)-- Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of Albany Molecular Research, Inc. (“AMRI”) (NasdaqGS: AMRI) concerning the merger with The Carlyle Group. Under the terms of the agreement, valued at approximately $933 million, AMRI shareholders will only receive $21.75 in cash per AMRI share held. If you are an affected investor, and you want to learn more about the investigation or if you have informatio...
- Please Change Name Jonathan Kanarek
- CFA
Moody's places Albany Molecular's ratings on review for downgrade
Rating Action: Moody's places Albany Molecular's ratings on review for downgrade. Global Credit Research- 07 Jun 2017. New York, June 07, 2017-- Moody's Investors Service placed the ratings of Albany Molecular Research, Inc. on review for downgrade, including the B3 Corporate Family Rating and B3-PD Probability of Default Rating.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Co...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Albany Molecular Research, Inc. (NASDAQGS:AMRI) stock prior to June 6, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Albany Molecular to The Carlyle Group and GTCR LLC for $21.75 per share. To learn more about the action and your rights, go to: http://www.zlkdocs.com/AMRI-Info-Request-Form-ma-5...
ALBANY MOLECULAR RESEARCH, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Albany Molecular Research, Inc. (NASDAQ GS: AMRI)? Did you purchase any of your shares prior to June 6, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Albany Molecular Research, Inc. (“AMRI” or the “Company”) (NASDAQ GS: ...
- Shelley Moen
Vermilion Compass: Weekly Equity Strategy
• Bullish big picture, but keep an eye on financials. Our message from last Tuesday carries over into this week: watch financials. They hold the key to the market's next move. Specifically, we are monitoring the XLF, whose daily chart still exhibits a potential, 6-month top pattern. The ETF has avoided, so far, a breakdown below the $23 level and 200-day MA. But it's premature to give the all clear. We're left with two possible outcomes: (1) XLF breaks below $23 and the 200-day, producing a ...
- Please Change Name Jonathan Kanarek
- CFA
Albany Molecular Research, Inc.: Update to Discussion of Key Rating Fa...
CORPORATES CREDIT OPINION 7 May 2017 Update RATINGS Albany Molecular Research, Inc. Domicile Albany, New York, United States Long Term Rating B3 Type LT Corporate Family Ratings Outlook Stable Please see the ratings section at the end of this report for more information. The ratings and outlook shown reflect information as of the publication date. Contacts Jonathan Kanarek, CFA 212-553-0340 VP-Sen
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.